- Home
- TACH vs SABS Comparison
TACH vs SABS Comparison
Compare TACH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TACH | SABS |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | 86 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 288.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TACH | SABS |
|---|---|---|
| Price | $10.42 | $3.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 182.6K | ★ 821.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.06 | $1.67 |
| 52 Week High | $10.48 | $6.60 |
Technical Indicators
Market Signals| Indicator | TACH | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 64.75 | 55.04 |
| Support Level | $10.28 | $3.48 |
| Resistance Level | $10.48 | $4.10 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 75.00 | 61.54 |
Price Performance
Historical ComparisonAbout TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.